Literature DB >> 14710950

Immunity to cancer through immune recognition of altered self: studies with melanoma.

José A Guevara-Patiño1, Mary Jo Turk, Jedd D Wolchok, Alan N Houghton.   

Abstract

The adaptive immune system is capable of recognizing cancer through T- and B-cell receptors. However, priming adaptive immunity against self antigens is potentially a difficult task. Presentation of altered self to the immune system is a strategy to elicit immunity against poorly immunogenic antigens. We have shown that immunization with conserved paralogues of tumor antigens can induce adaptive immunity against self antigens expressed by cancer. Remarkably, cancer immunity elicited by closely related paralogues can generate distinct adaptive immune responses, either antibody or T-cell dependent. Cancer immunity induced by xenogeneic immunization follows multiple and alternative pathways. The effector phase of tumor immunity can be mediated by cytotoxic T cells or macrophages and perhaps natural killer cells for antibody-dependent immunity. Helper CD4+ T cells are typically, but not always, required to generate immunity. Autoimmunity is frequently observed following immunization. Cancer immunity and autoimmunity use overlapping mechanisms, and therefore they are difficult to uncouple, but distinct pathways can be discerned that open the eventual possibility of uncoupling tumor immunity from autoimmunity. Studies examining the molecular basis for immunogenicity of conserved paralogues are facilitating the development of new strategies to rationally design vaccines that trigger adaptive immune responses to cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14710950     DOI: 10.1016/s0065-230x(03)90005-4

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  17 in total

1.  Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.

Authors:  Emily C Bellavance; Frederick J Kohlhapp; Andrew Zloza; Jeremy A O'Sullivan; James McCracken; Michael C Jagoda; Andrew T Lacek; Mitchell C Posner; Jose A Guevara-Patino
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

2.  Heteroleptic Ruthenium Polypyridyl Complex Had Differential Effects on the Production of Pro-inflammatory Cytokines TNFα, IL1β, and IL6 by the Mammalian Macrophages In Vitro.

Authors:  Furkan Ayaz
Journal:  Inflammation       Date:  2019-08       Impact factor: 4.092

3.  Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.

Authors:  Michael J Ciesielski; Manmeet S Ahluwalia; Stephan A Munich; Molly Orton; Tara Barone; Asher Chanan-Khan; Robert A Fenstermaker
Journal:  Cancer Immunol Immunother       Date:  2010-04-27       Impact factor: 6.968

4.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Authors:  Christiane Meyer; Alexandra Sevko; Marcel Ramacher; Alexandr V Bazhin; Christine S Falk; Wolfram Osen; Ivan Borrello; Masashi Kato; Dirk Schadendorf; Michal Baniyash; Viktor Umansky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

Review 5.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

6.  Ruthenium pyridyl thiocyanate complex increased the production of pro-inflammatory TNFα and IL1β cytokines by the LPS stimulated mammalian macrophages in vitro.

Authors:  Furkan Ayaz
Journal:  Mol Biol Rep       Date:  2018-10-04       Impact factor: 2.316

7.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Prevalence of antitumor antibodies in laying hen model of human ovarian cancer.

Authors:  Animesh Barua; Seby L Edassery; Pincas Bitterman; Jacques S Abramowicz; Angela L Dirks; Janice M Bahr; Dale B Hales; Michael J Bradaric; Judith L Luborsky
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

9.  Enhanced interferon-gamma secretion and antitumor activity of T-lymphocytes activated by dendritic cells loaded with glycoengineered myeloma antigens.

Authors:  Hong Xiong; Qiu-ye Wu; Hong-gang Hu; Ban Liu; Zhong-wu Guo; Daniel Man-yuan Sze; Jian Hou
Journal:  Chin Med J (Engl)       Date:  2007-10-05       Impact factor: 2.628

10.  Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment.

Authors:  Anna-Karin Roos; Fredrik Eriksson; James A Timmons; Josefine Gerhardt; Ulrika Nyman; Lindvi Gudmundsdotter; Andreas Bråve; Britta Wahren; Pavel Pisa
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.